Table 1.
Clinical characteristics of pediatric Glioblastoma Multiforme (pGBM)
| ID | Gender | Age at diagnosis (years) | Surgery | First-line Treatment | Response | FU (months) | Status |
|---|---|---|---|---|---|---|---|
| P1 | F | 12 | PTR | TMZ + RT | PR | 8 | DOD |
| P2 | F | 1 | GTR | HDCT - RT | CR | 14 | DOD |
| P3 | M | 9 | PTR | Vinorelbine + RT | PR | 12 | DOD |
| P4 | F | 1 | GTR | HDCT + RT | CR | 24 | DOD |
| P5 | M | 4 | PTR | HDCT - RT | PR | 3 | DOD |
| P6 | F | 8 | PTR | Vinorelbine + RT | PR | 19 | DOD |
| P7 | M | 15 | PTR | Vinorelbine + RT | PR | 8 | DOD |
| P8 | M | 12 | By | TMZ + RT | PR | 7 | DOD |
| P9 | F | 7 | PTR | TMZ + RT | PR | 10 | DOD |
GTR: gross total removal; PTR: partial total removal; By: biopsy; HDCT: high-dose chemotherapy; RT: radiotherapy; TMZ: temozolomide; CR: complete response; PR: partial response; FU: follow-up; AWD: alive with disease; DOD: dead of disease.